Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 17/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.42 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.42 |
| ▸ | STAT6 | P42226 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7012855 | 0.89 | NPY1R (0.56) | NPY1RKCNH2 | |
| SCHEMBL7009294 | 0.89 | NPY1R (0.55) | NPY1RKCNH2 | |
| SCHEMBL7019032 | 0.89 | NPY1R (0.55) | NPY1RKCNH2 | |
| SCHEMBL7016178 | 0.87 | NPY1R (0.50) | NPY1R | |
| SCHEMBL7013811 | 0.85 | NPY1R (0.51) | NPY1RKCNH2 | |
| SCHEMBL12946434 | 0.85 | NPY1R (0.51) | NPY1RKCNH2 | |
| SCHEMBL7011726 | 0.85 | NPY1R (0.51) | NPY1RKCNH2 | |
| SCHEMBL7017636 | 0.84 | NPY1R (0.50) | NPY1RKCNH2 | |
| SCHEMBL7018007 | 0.84 | NPY1R (0.47) | NPY1RKCNH2 | |
| SCHEMBL7011569 | 0.83 | NPY1R (0.48) | NPY1RMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110015181-A1 | ALKYLAMINOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-01-20 | — | — | US | disclosed |
| US-20110015181-A1 | ALKYLAMINOPYRIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2011-01-20 | — | — | US | disclosed |
| EP-2264026-A1 | ALKYLAMINOPYRIDINE DERIVATIVE | Banyu Pharmaceutical Co., Ltd. (JP) | 2010-12-22 | — | — | EP | disclosed |
| EP-0889034-B1 | AMINOPYRIDINE DERIVATIVES | BANYU PHARMA CO LTD (JP) | 2003-09-17 | — | — | EP | disclosed |
| US-6011039-A | USEFUL AS NEUROPEPTIDE Y RECEPTOR ANTAGONISTS; TREATING HYPERPHAGIA, OBESITY OR DIABETES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2000-01-04 | — | — | US | disclosed |
| EP-0889034-A1 | AMINOPYRIDINE DERIVATIVES | BANYU PHARMACEUTICAL CO., LTD. (JP) | 1999-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015181-A1 | ALKYLAMINOPYRIDINE DERIVATIVE | NPY4R, NPY1R, NPY2R | NPY1R 2/4885LMNA 3108/4885MAPT 4883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.